Estradiol/DRSP (Angeliq, BAY86-4891)
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
82
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Postmenopause
Conditions
Postmenopause
Trial Timeline
Sep 1, 2005 โ Dec 1, 2006
NCT ID
NCT00185328About Estradiol/DRSP (Angeliq, BAY86-4891)
Estradiol/DRSP (Angeliq, BAY86-4891) is a approved stage product being developed by Bayer for Postmenopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00185328. Target conditions include Postmenopause.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00185328 | Approved | Completed |
Competing Products
16 competing products in Postmenopause